This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Women's Health, Other  • Oncology  • Breast Cancer  • Adverse Effects  • Alert me on articles by topic

JAMA. 2008;299(9):1055-1056.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a Clinical Crossroads article published in March 2006,¹ Steven E. Come, MD, discussed a 62-year-old woman with a new diagnosis of breast cancer. Ms T underwent a routine mammogram, which had abnormal results. After an ultrasound and biopsy, Ms T was found to have clinical stage I carcinoma of her left breast. She had no family history of breast or ovarian cancer. Her medical history was remarkable for osteopenia.

Ms T was considered a good candidate for breast conservation therapy and underwent a wire localized excisional biopsy in November 2004. Final pathological findings revealed an infiltrating lobular carcinoma with an invasive component of 9 mm and a histologic grade of 2 (out of 3). Given her good prognosis, age, and positive estrogen and progesterone receptors, she underwent radiation treatment to the left breast and was prescribed tamoxifen. Ms T wondered whether an aromatase inhibitor (AI) would be superior to . . . [Full Text of this Article]

MS T

Nadine Farag, BS; Risa Burns, MD; Steven E. Come, MD